Mutations in calreticulin (CALR) were recently described to be present in the majority of patients with a JAK2-unmutated myeloproliferative neoplasm (MPN). 1, 2 This discovery has had rapid clinical impact, and testing for CALR has been embedded in national and international diagnostic guidelines. [3] [4] [5] However, a human MPN-derived cell line harboring a CALR mutation has not been reported and the mechanisms by which mutated-CALR results in an MPN remain unclear.
To begin to investigate the pathogenetic consequences of mutant CALR, we searched for patient-derived cell lines harboring CALR mutations. None were identified by exome sequencing of 1015 cell lines, including 37 derived from hematopoietic neoplasms. 1 We therefore looked for cell lines derived from patients with leukemic transformation of a preceding MPN. Given that CALR and JAK2 mutations are almost completely mutually exclusive, 1,2,6 we focused on four such lines known to lack a JAK2 mutation (MONO-MAC-6, MARIMO, GDM-1 and ELF-153), and also tested a further 52 other predominantly myeloid cell lines (Supplementary Table 1) . Mutation screening was done by Sanger sequencing as previously described, 1 and details of other methods are in the Supplementary Information.
The only cell line found to harbor a CALR mutation was MARIMO, originally derived from a 68-year-old female with AML-M2, and an antecedent history of ET. 7 MARIMO is negative for JAK2V617F and MPL exon 10 mutations (data not shown) and carries a heterozygous 61-basepair (bp) deletion in CALR exon 9 (c.1099_1159del; L367fs*43), which, like all other reported CALR mutations, results in a +1-bp shift in the reading frame and thus generates a novel C terminus (Figure 1a) . In patients, the commonest two CALR mutations, accounting for 85% of cases, are a 52-bp deletion (type 1; c.1099_1150del; L367fs*46) and a 5-bp insertion (type 2; c.1154_1155_ins; Accepted article preview online 24 September 2014; advance online publication, 17 October 2014 K385fs*47). 8 Both the type 1 deletion and the MARIMO deletion are immediately preceded by a nucleotide sequence identical to that at the 3' end of the deletion (Figure 1a Graph depicts all data points generated in two independent experiments performed in duplicate. ***P o0.001 (e) Western blot showing total CALR protein levels of MARIMO and four other myeloid cell lines.
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Allele-specific PCR demonstrated expression of the mutant CALR allele (Figure 1c) . Compared with other cell lines derived from patients with JAK2V617F (HEL, UKE-1 and SET-2) or CML (K562) total CALR mRNA levels were 10-fold higher in MARIMO (Figure 1d ) and total CALR protein levels were also increased albeit more modestly (Figure 1e) .
MARIMO cells expressed cell surface marker CD15 but not other progenitor or lineage-affiliated markers (Supplementary Table 2 ). The proliferation and cell cycle status of MARIMO was unremarkable compared with other myeloid lines (Supplementary Figure 1) . We next analysed cellular calcium stores since CALR has an important role in endoplasmic reticulum (ER) mediated calcium homeostasis 9 and mutant CALR protein lacks variable numbers of calcium binding sites present in the wild-type C terminus. No significant differences in basal cytoplasmic calcium levels were found amongst the six cell lines tested (Figure 2a) . Cell lines were then treated with 1 μM thapsigargin, which blocks ER Ca 2+ -ATPase channels resulting in ER calcium depletion and increased cytosolic calcium levels. 10 MARIMO cells showed the slowest rate of increase of cytoplasmic calcium levels upon addition of thapsigargin (Figure 2b) , consistent with the concept that mutant CALR alters ER dependent calcium homeostasis.
The mutual exclusivity of JAK2 and CALR mutations argues that they may share pathogenetic mechanisms and has been used to suggest that CALR mutations may activate JAK2/STAT5 signaling. This concept is supported by expression profiling of patient-derived granulocytes 11 together with a report that expression of CALR in Ba/ F3 cells confers interleukin-3 independence and is accompanied by increased STAT5 phosphorylation. 2 However other studies have reported distinct transcriptional signatures in JAK2V617F-mutated and JAK2V617F-unmutated MPNs. 12, 13 Interpretation of these apparently conflicting results is complicated by several issues including limitations of overexpression systems, the uncertain relevance of granulocytes to disease pathogenesis and difficulties inherent to studies of signaling in primary cells containing variable proportions of mutant cells. To circumvent some of these issues, and to gain insight into the consequences of CALR mutations, we explored the properties of MARIMO cells.
The dependence of MARIMO cells on JAK signaling was initially assessed using the JAK inhibitors Tofacitinib (a JAK2/3 inhibitor) and JAK-inhibitor-I (a pan-JAK inhibitor) (Supplementary Figure 2) . MARIMO cells were more resistant to both inhibitors than seven cell lines harboring mutant JAK2 or JAK3. Dose response studies using the clinically approved JAKinhibitor Ruxolitinib (INCB018424, a JAK1/2 inhibitor) showed that HEL and UKE-1 (both JAK2V617F positive) had IC 50 values of 217 and 430 nM, respectively (Figure 2c) . In marked contrast the IC 50 value for MARIMO was greater than 10 000 nM, demonstrating that MARIMO was not dependent on JAK2 signaling. Consistent with these data, western blot analysis showed that, compared with JAK2-mutant cells, MARIMO cells contained markedly reduced levels of JAK2, phosphorylated-JAK2 (pJAK2), STAT5 and pSTAT5 (Figure 2d ). The lack of JAK2-STAT5 signaling was not accompanied by a compensatory increase in STAT1 or STAT3 phosphorylation (Figure 2e ). JAK2 transcript levels in MARIMO were similar to other cell lines (Figure 2f ), suggesting either decreased translation or increased degradation of JAK2.
Together, our data demonstrate that the MARIMO cell line harbors a CALR mutation and yet is not dependent on JAK/STAT signaling, in marked contrast to JAK2-mutated cell lines. Our results therefore raise the possibility that mutations of CALR and JAK2 may share activation of pathways other than the STATs. Superficially our data appear to contrast with reports that JAK2-unmutated and CALR-mutated MF patients respond to ruxolitinib. 14, 15 However in JAK2V617F-positive patients studies of mutant allele burden show that Ruxolitinib has a minimal effect on the mutant clone. 15 It is therefore likely that the clinical responses to Ruxolitinib (reduced splenomegaly and improved constitutional symptoms) do not reflect a cytotoxic effect of the drug on the neoplastic clone, but instead are at least in part due to down-modulation of pro-inflammatory signaling cascades. 16 
